vs
IMMUCELL CORP（ICCC）与林德（LIN）财务数据对比。点击上方公司名可切换其他公司
林德的季度营收约是IMMUCELL CORP的1.6倍（$8.8M vs $5.5M），林德同比增速更快（8.2% vs -8.4%），林德自由现金流更多（$898.0K vs $-1.8M），过去两年IMMUCELL CORP的营收复合增速更高（3.9% vs -96.7%）
ImmuCell Corp是一家总部位于美国的动物健康生物技术企业，主要研发、生产和销售以奶牛为主的家畜相关保健与治疗产品，核心产品包括乳腺炎等常见牛类疾病的防治方案，主要服务北美地区的畜牧养殖户和兽医机构。
林德是全球知名跨国化工企业，按市场份额及营收计为全球最大工业气体供应商。公司1879年由德国科学家、工程师卡尔·冯·林德在德国威斯巴登创立，现总部位于英国沃金，在爱尔兰注册，2018年由原林德股份公司与1907年在美国成立的普莱克斯合并组建。
ICCC vs LIN — 直观对比
营收规模更大
LIN
是对方的1.6倍
$5.5M
营收增速更快
LIN
高出16.7%
-8.4%
自由现金流更多
LIN
多$2.7M
$-1.8M
两年增速更快
ICCC
近两年复合增速
-96.7%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.5M | $8.8M |
| 净利润 | $-139.7K | — |
| 毛利率 | 42.9% | 48.5% |
| 营业利润率 | 0.4% | 27.8% |
| 净利率 | -2.5% | — |
| 营收同比 | -8.4% | 8.2% |
| 净利润同比 | 80.1% | — |
| 每股收益（稀释后） | $-0.02 | $3.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICCCLIN
| Q1 26 | — | $8.8M | ||
| Q4 25 | — | $8.8B | ||
| Q3 25 | $5.5M | $8.6B | ||
| Q2 25 | $6.4M | $8.5B | ||
| Q1 25 | $8.1M | $8.1B | ||
| Q4 24 | $7.8M | $8.3B | ||
| Q3 24 | $6.0M | $8.4B | ||
| Q2 24 | $5.5M | $8.3B |
净利润ICCCLIN
| Q1 26 | — | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | $-139.7K | $1.9B | ||
| Q2 25 | $501.9K | $1.8B | ||
| Q1 25 | $1.4M | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $-701.7K | $1.6B | ||
| Q2 24 | $-1.5M | $1.7B |
毛利率ICCCLIN
| Q1 26 | — | 48.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 43.7% | — | ||
| Q1 25 | 41.6% | — | ||
| Q4 24 | 36.5% | — | ||
| Q3 24 | 26.3% | — | ||
| Q2 24 | 22.5% | — |
营业利润率ICCCLIN
| Q1 26 | — | 27.8% | ||
| Q4 25 | — | 23.0% | ||
| Q3 25 | 0.4% | 27.5% | ||
| Q2 25 | 8.8% | 27.7% | ||
| Q1 25 | 13.9% | 26.9% | ||
| Q4 24 | 8.0% | 27.4% | ||
| Q3 24 | -9.6% | 25.0% | ||
| Q2 24 | -25.3% | 26.4% |
净利率ICCCLIN
| Q1 26 | — | — | ||
| Q4 25 | — | 17.5% | ||
| Q3 25 | -2.5% | 22.4% | ||
| Q2 25 | 7.8% | 20.8% | ||
| Q1 25 | 17.9% | 20.6% | ||
| Q4 24 | — | 20.8% | ||
| Q3 24 | -11.7% | 18.5% | ||
| Q2 24 | -28.0% | 20.1% |
每股收益（稀释后）ICCCLIN
| Q1 26 | — | $3.98 | ||
| Q4 25 | — | $3.28 | ||
| Q3 25 | $-0.02 | $4.09 | ||
| Q2 25 | $0.06 | $3.73 | ||
| Q1 25 | $0.16 | $3.51 | ||
| Q4 24 | $0.09 | $3.61 | ||
| Q3 24 | $-0.09 | $3.22 | ||
| Q2 24 | $-0.20 | $3.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.9M | $4.0M |
| 总债务越低越好 | $9.5M | $24.7M |
| 股东权益账面价值 | $29.8M | $40.1M |
| 总资产 | $45.7M | $86.3M |
| 负债/权益比越低杠杆越低 | 0.32× | 0.62× |
8季度趋势，按日历期对齐
现金及短期投资ICCCLIN
| Q1 26 | — | $4.0M | ||
| Q4 25 | — | $5.1B | ||
| Q3 25 | $3.9M | $4.5B | ||
| Q2 25 | — | $4.8B | ||
| Q1 25 | — | $5.3B | ||
| Q4 24 | $3.8M | $4.8B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | $1.3M | $4.6B |
总债务ICCCLIN
| Q1 26 | — | $24.7M | ||
| Q4 25 | — | $20.7B | ||
| Q3 25 | $9.5M | $18.6B | ||
| Q2 25 | — | $19.7B | ||
| Q1 25 | $8.7M | $17.6B | ||
| Q4 24 | $9.0M | $15.3B | ||
| Q3 24 | $9.4M | $17.5B | ||
| Q2 24 | $9.8M | $16.9B |
股东权益ICCCLIN
| Q1 26 | — | $40.1M | ||
| Q4 25 | — | $38.2B | ||
| Q3 25 | $29.8M | $38.6B | ||
| Q2 25 | $29.9M | $38.5B | ||
| Q1 25 | $29.0M | $38.0B | ||
| Q4 24 | $27.5M | $38.1B | ||
| Q3 24 | $26.4M | $39.2B | ||
| Q2 24 | $23.5M | $38.2B |
总资产ICCCLIN
| Q1 26 | — | $86.3M | ||
| Q4 25 | — | $86.8B | ||
| Q3 25 | $45.7M | $86.0B | ||
| Q2 25 | $46.7M | $86.1B | ||
| Q1 25 | $45.6M | $82.7B | ||
| Q4 24 | $45.1M | $80.1B | ||
| Q3 24 | $44.4M | $82.5B | ||
| Q2 24 | $41.9M | $80.2B |
负债/权益比ICCCLIN
| Q1 26 | — | 0.62× | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | 0.32× | 0.48× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | 0.30× | 0.46× | ||
| Q4 24 | 0.33× | 0.40× | ||
| Q3 24 | 0.36× | 0.45× | ||
| Q2 24 | 0.42× | 0.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $898.0K |
| 自由现金流率自由现金流/营收 | -32.3% | 10.2% |
| 资本支出强度资本支出/营收 | 10.8% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $715.4K | $4.2B |
8季度趋势，按日历期对齐
经营现金流ICCCLIN
| Q1 26 | — | — | ||
| Q4 25 | — | $3.0B | ||
| Q3 25 | $-1.2M | $2.9B | ||
| Q2 25 | $1.6M | $2.2B | ||
| Q1 25 | $1.6M | $2.2B | ||
| Q4 24 | $-3.1K | $2.8B | ||
| Q3 24 | $-639.3K | $2.7B | ||
| Q2 24 | $581.8K | $1.9B |
自由现金流ICCCLIN
| Q1 26 | — | $898.0K | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | $-1.8M | $1.7B | ||
| Q2 25 | $1.4M | $954.0M | ||
| Q1 25 | $1.2M | $891.0M | ||
| Q4 24 | $-199.3K | $1.6B | ||
| Q3 24 | $-727.7K | $1.7B | ||
| Q2 24 | $471.0K | $796.0M |
自由现金流率ICCCLIN
| Q1 26 | — | 10.2% | ||
| Q4 25 | — | 17.9% | ||
| Q3 25 | -32.3% | 19.4% | ||
| Q2 25 | 22.4% | 11.2% | ||
| Q1 25 | 15.4% | 11.0% | ||
| Q4 24 | -2.6% | 18.8% | ||
| Q3 24 | -12.1% | 19.9% | ||
| Q2 24 | 8.6% | 9.6% |
资本支出强度ICCCLIN
| Q1 26 | — | — | ||
| Q4 25 | — | 16.6% | ||
| Q3 25 | 10.8% | 14.8% | ||
| Q2 25 | 2.4% | 14.8% | ||
| Q1 25 | 4.1% | 15.7% | ||
| Q4 24 | 2.5% | 15.1% | ||
| Q3 24 | 1.5% | 12.8% | ||
| Q2 24 | 2.0% | 13.7% |
现金转化率ICCCLIN
| Q1 26 | — | — | ||
| Q4 25 | — | 1.98× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | 3.19× | 1.25× | ||
| Q1 25 | 1.09× | 1.29× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.76× | ||
| Q2 24 | — | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
